Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Hanmi Pharmaceutical
IR Event | Hanmi Pharmaceutical
We Provide Transparent Information About Our Company to Shareholders.
Aptose Biosciences Announces Completion Of Acquisition By Hanmi Pharmaceutical
Aptose Biosciences Announces Completion Of Acquisition By Hanmi Pharmaceutical 2026-06-30 07:46:03 (MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc.
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide(LAPSGLP-2 analog) Lilly licenses Hanmi’s sonefpeglutide(LAPSGLP-2 analog) for multiple indications (June 1, 2026) SEOUL, South Korea, June 1, 2026 - Hanmi Pharm. Co., Ltd. (“Hanmi”) today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi’s biologic drug candidate sonefpeglutide (LAPSGLP-2 analog) with Eli Lilly and Company (“Lilly”).
Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático
Hanmi Pharmaceutical Medicamentos cardiovasculares y respiratorios se suministrarán en Malasia y Filipinas Shin Hae-gon (derecha), director de ventas internacionales de Hanmi Pharmaceutical, y Andreas Daugaard Jørgensen (izquierda), director general del clúster Asia-Pacífico de Organon, se reunieron en la oficina de Organon en Malasia para analizar la expansión de las terapias combinadas de Hanmi en el mercado del Sudeste Asiático.
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia Original
SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies’ partnership in Southeast Asia.
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments kAmkDA2? 4=2DDlQ=686?5$A2?r=2DDQm$t~&{[ $@FE9 z@C62k^DA2?m[ kDA2?
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments , /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment.
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
kAmkDEC@?8mw2?>: $:8?D tI4=FD:G6 !2CE?6CD9:A H:E9 }6H |6I:42? !2CE?6C {23@C2E@C:@D $2?76C[ r@G6C:?8 t7A68=6?2E:56 2?5 s:236E6D %C62E>6?EDk^DEC@?8m k^Am kAmkDA2? 4=2DDlQ=686?5$A2?r=2DDQm$t~&{[ $@FE9 z@C62k^DA2?m[ kDA2?
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
By Hanmi Pharmaceutical Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment.
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Personalised advertising and content, advertising and content measurement, audience research and services development Store and/or access information on a device You can choose how your personal data is used.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Hanmi
Contact Hanmi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack